 NEW YORK, Jan. 11, 2023 GLOBE NEWSWIRE MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T iNKT cell therapies to treat cancer and other immune-mediated diseases, announced that Dr. Jennifer Buell, President and CEO of MiNK, will participate in a fireside chat at ... The post MiNK Therapeutics to Participate in B. Riley Securities Oncology Conference appeare... 